Next Article in Journal
Development of New Drugs for Autoimmune Hemolytic Anemia
Previous Article in Journal
Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
Previous Article in Special Issue
Melatonin-Eluting Contact Lenses Effect on Tear Volume: In Vitro and In Vivo Experiments
Article

Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel

1
Department of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS 38677, USA
2
Research Institute of Pharmaceutical Sciences, University of Mississippi, Oxford, MS 38677, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Priyanka Agarwal, Thakur Raghu Raj Singh and Marina Gallarate
Pharmaceutics 2022, 14(5), 1034; https://doi.org/10.3390/pharmaceutics14051034
Received: 16 March 2022 / Revised: 5 May 2022 / Accepted: 8 May 2022 / Published: 11 May 2022
(This article belongs to the Special Issue Nanotechnology in Ocular Drug Delivery)
The management of retinoblastoma (RB) involves the use of invasive treatment regimens. Paclitaxel (PTX), an effective antineoplastic compound used in the treatment of a wide range of malignant tumors, poses treatment challenges due to systemic toxicity, rapid elimination, and development of resistance. The goal of this work was to develop PTX-loaded, α-tocopherol succinate (αTS)-based, nanostructured lipid carrier (NLCs; αTS-PTX-NLC) and PEGylated αTS-PTX-NLC (αTS-PTX-PEG-NLC) to improve ocular bioavailability. The hot homogenization method was used to prepare the NLCs, and repeated measures ANOVA analysis was used for formulation optimization. αTS-PTX-NLC and αTS-PTX-PEG-NLC had a mean particle size, polydispersity index and zeta potential of 186.2 ± 3.9 nm, 0.17 ± 0.03, −33.2 ± 1.3 mV and 96.2 ± 3.9 nm, 0.27 ± 0.03, −39.15 ± 3.2 mV, respectively. The assay and entrapment efficiency of both formulations was >95.0%. The NLC exhibited a spherical shape, as seen from TEM images. Sterilized (autoclaved) formulations were stable for up to 60 days (last time point checked) under refrigerated conditions. PTX-NLC formulations exhibited an initial burst release and 40% drug release, overall, in 48 h. The formulations exhibited desirable physicochemical properties and could lead to an effective therapeutic option in the management of RB. View Full-Text
Keywords: paclitaxel; α-tocopherol succinate; retinoblastoma; NLC; ocular drug delivery paclitaxel; α-tocopherol succinate; retinoblastoma; NLC; ocular drug delivery
Show Figures

Graphical abstract

MDPI and ACS Style

Marathe, S.; Shadambikar, G.; Mehraj, T.; Sulochana, S.P.; Dudhipala, N.; Majumdar, S. Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel. Pharmaceutics 2022, 14, 1034. https://doi.org/10.3390/pharmaceutics14051034

AMA Style

Marathe S, Shadambikar G, Mehraj T, Sulochana SP, Dudhipala N, Majumdar S. Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel. Pharmaceutics. 2022; 14(5):1034. https://doi.org/10.3390/pharmaceutics14051034

Chicago/Turabian Style

Marathe, Sushrut, Gauri Shadambikar, Tabish Mehraj, Suresh P. Sulochana, Narendar Dudhipala, and Soumyajit Majumdar. 2022. "Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel" Pharmaceutics 14, no. 5: 1034. https://doi.org/10.3390/pharmaceutics14051034

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop